Inflammatix Inc (Inflammatix) is a molecular diagnostics company developing host response-based diagnostic tests that read the immune system to resolve major clinical and public health challenges. Inflammatix's HostDx Sepsis test is used to identify or diagnose acute infections and sepsis in ED or urgent care clinics; traumatic injuries; neonate and ICU patient monitoring scenarios; and HostDx Fever test is used to diagnose bacterial infection in outpatient clinics and urgent care centers. The company strives to develop tests for acute bacterial and viral infections, sepsis, tropical infections, autoimmune diseases, and transplant rejection based on patent-pending biomarkers licensed from Stanford University. Inflammatix is headquartered in Burlingame, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Inflammatix Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Inflammatix Inc Company Overview
- Inflammatix Inc Company Snapshot
- Inflammatix Inc Pipeline Products and Ongoing Clinical Trials Overview
- Inflammatix Inc - Pipeline Analysis Overview
- Inflammatix Inc - Key Facts
- Inflammatix Inc - Major Products and Services
- Inflammatix Inc Pipeline Products by Development Stage
- Inflammatix Inc Ongoing Clinical Trials by Trial Status
- Inflammatix Inc Pipeline Products Overview
- CoVerity COVID-19 Severity Test
- CoVerity COVID-19 Severity Test Product Overview
- Diagnostic Test - Acute Solid-Organ Transplant Rejection
- Diagnostic Test - Acute Solid-Organ Transplant Rejection Product Overview
- Diagnostic Test - Dengue
- Diagnostic Test - Dengue Product Overview
- Diagnostic Test - Myocardial Infarction
- Diagnostic Test - Myocardial Infarction Product Overview
- FluVID-HR
- FluVID-HR Product Overview
- HostDx FeverFlu
- HostDx FeverFlu Product Overview
- HostDx TROPICAL FEVER
- HostDx TROPICAL FEVER Product Overview
- HostDxEndotypes
- HostDxEndotypes Product Overview
- HostDxINSEP
- HostDxINSEP Product Overview
- HostDxINSEP Clinical Trial
- HostDxTNFresponse
- HostDxTNFresponse Product Overview
- Myrna Test System
- Myrna Test System Product Overview
- TriVerity Acute Infection And Sepsis Test System
- TriVerity Acute Infection And Sepsis Test System Product Overview
- ViraBac EZ Test
- ViraBac EZ Test Product Overview
- ViraBac+
- ViraBac+ Product Overview
- Inflammatix Inc - Key Competitors
- Inflammatix Inc - Key Employees
- Inflammatix Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- Inflammatix Inc, Recent Developments
- Nov 29, 2023: Inflammatix receives breakthrough device designation for TriVerity system
- Nov 15, 2023: Inflammatix Completes Technical Development for Triverity Acute Infection and Sepsis Test System
- Jul 10, 2023: Inflammatix Appoints Heiner Dreismann as New Board Member
- Jun 15, 2022: Inflammatix Appoints Purvesh Khatri as Chief Scientific Officer
- Nov 18, 2021: Inflammatix announces additional $12.1 million funding from BARDA for ViraBac EZ acute infection test
- Apr 15, 2021: Inflammatix Appoints Amy Boyle as Chief Operating Officer
- Oct 29, 2020: Inflammatix announces $7.4 million in additional BARDA funding to advance ViraBac EZ acute infection test
- Sep 29, 2020: DARPA awards Inflammatix up to $1.1 million to develop diagnostic that predicts COVID-19 severity risk
- Apr 20, 2020: Study demonstrates substantial cost savings in health economic model of the Inflammatix Host-Response Test for sepsis
- Mar 04, 2020: New Inflammatix study in nature communications outlines breakthrough in diagnosing acute infections by reading the immune system
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Inflammatix Inc Pipeline Products and Ongoing Clinical Trials Overview
- Inflammatix Inc Pipeline Products by Equipment Type
- Inflammatix Inc Pipeline Products by Indication
- Inflammatix Inc Ongoing Clinical Trials by Trial Status
- Inflammatix Inc, Key Facts
- Inflammatix Inc, Major Products and Services
- Inflammatix Inc Number of Pipeline Products by Development Stage
- Inflammatix Inc Pipeline Products Summary by Development Stage
- Inflammatix Inc Ongoing Clinical Trials by Trial Status
- Inflammatix Inc Ongoing Clinical Trials Summary
- CoVerity COVID-19 Severity Test - Product Status
- CoVerity COVID-19 Severity Test - Product Description
- Diagnostic Test - Acute Solid-Organ Transplant Rejection - Product Status
- Diagnostic Test - Acute Solid-Organ Transplant Rejection - Product Description
- Diagnostic Test - Dengue - Product Status
- Diagnostic Test - Dengue - Product Description
- Diagnostic Test - Myocardial Infarction - Product Status
- Diagnostic Test - Myocardial Infarction - Product Description
- FluVID-HR - Product Status
- FluVID-HR - Product Description
- HostDx FeverFlu - Product Status
- HostDx FeverFlu - Product Description
- HostDx TROPICAL FEVER - Product Status
- HostDx TROPICAL FEVER - Product Description
- HostDxEndotypes - Product Status
- HostDxEndotypes - Product Description
- HostDxINSEP - Product Status
- HostDxINSEP - Product Description
- HostDxINSEP - HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients with Suspected Infections and Suspected Sepsis
- HostDxTNFresponse - Product Status
- HostDxTNFresponse - Product Description
- Myrna Test System - Product Status
- Myrna Test System - Product Description
- TriVerity Acute Infection And Sepsis Test System - Product Status
- TriVerity Acute Infection And Sepsis Test System - Product Description
- ViraBac EZ Test - Product Status
- ViraBac EZ Test - Product Description
- ViraBac+ - Product Status
- ViraBac+ - Product Description
- Inflammatix Inc, Key Employees
- Glossary
- Inflammatix Inc Pipeline Products by Equipment Type
- Inflammatix Inc Pipeline Products by Development Stage
- Inflammatix Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Co-Diagnostics Inc
- Meridian Bioscience Inc
- NanoString Technologies Inc
- NanoString Technologies Inc
- Co-Diagnostics Inc
- Meridian Bioscience Inc
